2024

In January, Lidocaine Hydrochloride Injection passed the bioequivalence evaluation for generic drugs. In February, we were honored as one of the "Top 20 Industrial Enterprises in Wenling City for 2023." In February, it was recognized as a "Sixth Batch Provincial-Level Employment Internship Demonstration Base." In March, the registration application for tenofovir alafenamide fumarate as a chemical API was approved. In March, we were praised by the National Center for Adverse Drug Reaction Monitoring for safeguarding public health. In March, Ginkgo Leaf Dropping Pills were recognized as one of the first "Zhejiang-produced Traditional Chinese Medicine" industry brands. In April, the bifendate API passed the on-site inspection by South Korea's MFDS. In April, two drug products—clozapine tablets and calcium citrate tablets—launched their "large-print" package inserts for sale, making them among the first in China to adopt age-friendly labeling guidelines. In April, the Class 1 traditional Chinese medicine new drug, Lixiao Pi Granules, received approval from the Ethics Committee and has now initiated its Phase II clinical trial. In May, Huperzine A, used to treat hypoxic-ischemic encephalopathy (HIE) in newborns, received dual designation from the U.S. Food and Drug Administration (FDA): both Rare Pediatric Disease and Orphan Drug status. In May, the brand was recognized on the 2024 China Brand Value Evaluation List in the Autonomous Innovation Brands category, boasting a brand strength of 686 and a brand value of 1.814 billion yuan. Notably, the brand value reached a new all-time high, representing a 5.53% increase compared to last year. In May, Ye Yang, Secretary of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Professor Liu Jia, Researcher; Professor Zhu Mulan from the Chenshan Science Center at the Center for Excellence in Molecular Plant Sciences, CAS; and Dr. Chen Yang and advisor Mr. Jin from Shanghai Jin Yangguang Biotechnology visited Wanbangde Pharmaceutical Group to jointly discuss matters related to enhancing the company’s core products—huperzine A and Ginkgo Leaf Dropping Pills. In May, the first postdoctoral fellow successfully completed their station, and three current fellows smoothly passed their mid-term evaluations. In June, the seminar on projects such as the controlled-release shikonin tablets was successfully held at the Academician and Expert Workstation, providing clear guidance for the product’s clinical trials and future research planning. In June, Ginkgo Leaf Dropping Pills proudly made it onto the "2024 China Pharmaceutical Brand List [Hospital Settings]—Cardiovascular and Cerebrovascular Disease Medications (Traditional Chinese Medicine)" list, marking the fifth consecutive year the product has topped this prestigious ranking. In August, the short film "No Problem or So-Called Issues" was awarded the "Potential-Level Prize" at the Zhejiang Province Brand Story Competition. In September, we donated 200,000 yuan to the Shitang Education Foundation in Wenling City, showing our care for education and supporting students as they pursue their dreams. In October, the U.S. Food and Drug Administration (FDA) provided feedback on the clinical study involving patients using Huperzine A controlled-release tablets (for Alzheimer's disease indication), accepting China's Phase 1 clinical data and offering FDA guidance on key issues related to the study design. In November, Chlorpromazine Hydrochloride Tablets were approved, becoming the first domestically produced product to pass the consistency evaluation. In November, Bedano® Phloroglucinol Injection was selected as a "2024 Zhejiang Province Outstanding Industrial Product." In December, the clinical trial application for a novel oral formulation of huperzine A (developmental product code WP107) to treat generalized myasthenia gravis was accepted by the U.S. Food and Drug Administration (FDA). In December, the clinical trial application for a new indication of the innovative drug Huperzine A Injection (developmental product code WP103) — targeting hypoxic-ischemic encephalopathy (HIE) in newborns — was accepted by the U.S. Food and Drug Administration (FDA). In December, the company was listed among the "Top 500 Zhejiang High-Tech Enterprises for Innovation Capability in 2024," and was also selected as one of the "Top 100 Companies in the Life & Health Industry Hub."

2023

In January, we were honored to be listed among the "Top 20 Industrial Enterprises in Wenling for 2022," ranking second on the list. In January, we obtained the Indian registration certificate for cimetidine. In February, it was honored with the title of "2022 Zhejiang Province Anti-Drug Model Unit for Integrity." In February, the company was named on the "Zhejiang Province Industry-Education Integration Enterprise List for 2021–2022." In February, the patent titled "Method for Determining the Content of Flavonol Glycosides in Ginkgo Leaf Droplets," application number 20211063404685, was granted. In March, the company won two major awards: "2021 Outstanding Brand Enterprise of Chinese Ethnic Medicine" (with its flagship product, Ginkgo Leaf Droplets) and "2021 Top 50 Fast-Growing Companies in China's Pharmaceutical Industry." In March, the company was proudly listed among the "Top 100 Traditional Chinese Medicine Enterprises of 2022," ranking 65th—up 22 places from last year. In April, the "Huperzine A Injection Medical Research and Exchange Symposium," hosted by the National Clinical Research Center for Neurological Diseases and organized by Wanbangde Pharmaceutical Group, was successfully held. In May, Wanbangde Pharmaceutical Group Co., Ltd. was listed on the independent innovation brand ranking with a brand strength of 713 and a brand value of 1.719 billion yuan, placing 12th overall. In May, a university-enterprise-local government research collaboration agreement was signed with the School of Pharmaceutical Sciences at Zhejiang University. From May to June, the postdoctoral research workstation picked up momentum, welcoming three newly appointed PhDs and adding fresh talent to our scientific research efforts. In June, the company’s flagship product, Wanbang Xinnuokang® Ginkgo Leaf Dropping Pills, was featured on the "2023 China Pharmaceutical Brand List—Hospital Terminal Ranking: Cardiovascular and Cerebrovascular Disease Medications (Traditional Chinese Medicine)" category. In June, the company was recognized as a four-star enterprise in the "2022 Taizhou City Enterprise Management Star Rating Evaluation." In June, "Key Technology Development and Demonstration Application of Network Formulation Science" won the Second Prize in the 2022 Ministry of Education Higher Education Outstanding Scientific Research Achievement Award for Scientific and Technological Progress. In July, the company won two major awards: "Top 100 Chinese Pharmaceutical Manufacturers 2022-2023" and "Top 50 Growing Companies in China's Pharmaceutical Industry 2022-2023." In July, the invention patent received the "24th China Patent Excellence Award" (Patent Title: A Fluorescent Probe with Aggregation-Induced Emission Properties, along with Its Preparation Method and Applications). In August, the symposium on Huperzine A Controlled-Release Tablets and Huperzine A Injection was successfully held, providing clear guidance for the product’s clinical trials and future research planning. In October, it was recognized as one of Zhejiang Province's "Second Batch of Key Provincial Academician Workstations," the only one in Taizhou. In November, we successfully hosted the 19th Taizhou Pharmaceutical Regulatory Salon, themed "Standardized Development of the MAH Pharmacovigilance System." In November, the company was listed among the "Top 500 Zhejiang Provincial High-Tech Enterprises in Innovation Capability," climbing 34 spots higher in the rankings compared to last year. In November, we were honored with the title of "2023 Taizhou City-Level Green Factory." In November, the QC group's achievement, "Improving the Qualified Rate of Finished Shihuajiamai Injection," won the Third Prize for Outstanding QC Achievements in Zhejiang Province. In November, the company earned multiple honors, including the second-place team award and the top individual overall physical fitness title at Taizhou City's inaugural Emergency Rescue Skills Competition for employees of hazardous chemical enterprises. In December, the company's flagship product, acetylcholinesterase inhibitor [Huperzine A], received FDA orphan drug designation for the treatment of myasthenia gravis.

2022

In February, we were honored with the title of "Top 10 Industrial Enterprises in Wenling City for 2021," ranking 4th among the winners. In February, Bedano® Phloroglucinol Injection successfully passed the generic drug consistency evaluation. In February, the project "Secondary Development of Traditional Chinese Medicine—Research on the Secondary Development of Ginkgo Leaf Dropping Pills" successfully passed the acceptance review by the Zhejiang Provincial Department of Science and Technology. In June, the first postdoctoral researcher successfully joined the station. In June, Wanbande Ambidex® Ambroxol Hydrochloride Injection received its generic drug registration certificate and is considered to have passed the consistency evaluation. In July, Wanbang Xinnuokang® Ginkgo Leaf Droplets earned a spot on the 2022 "China Pharmaceutical Brand Ranking" list—specifically, the Hospital Terminal List for Cardiovascular and Cerebrovascular Disease Medications (Traditional Chinese Medicine). In September, a strategic cooperation agreement was signed with Academician Ji-Zong Zhao and his team for the research on Huperzine A injection. In October, it was listed on the "2022 China Brand Value Evaluation – Independent Innovation Brands" list. In November, Wanbangde Fujian® Bromhexine Hydrochloride Injection received its generic drug registration certificate, officially recognized as having passed the consistency evaluation. In December, it was listed on the "2022 China's Most Promising Pharmaceutical Companies" list. In December, it was listed among the Top 500 High-Tech Enterprises in Zhejiang Province for Innovation Capability.

2021

In May, the R&D building was completed and put into operation. In October, a postdoctoral research station was established.

2020

In January, it was rebranded as Wanbande Pharmaceutical Group Co., Ltd. In February, Wanbangde successfully completed its restructuring and went public (stock code 002082), bringing its pharmaceutical group into the publicly listed company system.

2019

In March, Wanbande Pharmaceutical Group officially became a wholly-owned subsidiary of Wanbande Pharmaceutical Holdings Group Co., Ltd.